RESUMEN
Fifty-five patients with hepatocellular carcinoma were treated with oily anticancer agent SMANCS dissolved in Lipiodol (SMANCS-LPD). The local response rate after the first arterial infusion in all patients was 39%, against 63% in 27 patients with Lipiodol accumulation occupying more than two thirds of tumor areas. The infusion therapy with SMANCS-LPD is adapted for a vascular-rich hepatocellular carcinoma. An infusion of 4 mg of SMANCS was ineffective for patients with tumors distributing in bilateral lobes of liver. Thus, an increase of infusion dosage or repeated infusions were recommended for such cases.
Asunto(s)
Antineoplásicos/administración & dosificación , Carcinoma Hepatocelular/tratamiento farmacológico , Aceite Yodado/administración & dosificación , Neoplasias Hepáticas/tratamiento farmacológico , Anhídridos Maleicos/administración & dosificación , Neoplasias Primarias Múltiples/tratamiento farmacológico , Poliestirenos/administración & dosificación , Cinostatina/análogos & derivados , Anciano , Esquema de Medicación , Femenino , Arteria Hepática , Humanos , Infusiones Intraarteriales , Masculino , Persona de Mediana Edad , Cinostatina/administración & dosificaciónRESUMEN
Forty-four patients with hepatocellular carcinoma were treated with oily anticancer agent SMANCS dissolved in Lipiodol (SMANCS-LPD). The local response rate after the first arterial infusion in all patients was 39%, against 63% in 27 patients with Lipiodol accumulation occupying more than two third of tumor areas. Repeated arterial infusion of SMANCS-LPD did not enhance the therapeutic effect. An infusion of 4mg of SMANCS was ineffective for patients with tumors distributing in bilateral lobes of liver, and 6 mg was recommended for such cases.